Naji M | OMICS International
ISSN: 2475-7640

Journal of Clinical and Experimental Transplantation
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Indexed In
  • Google Scholar
  • RefSeek
  • Hamdard University
  • Publons
  • Euro Pub
  • Geneva Foundation for Medical Education and Research
Share This Page

Naji M


Alemtuzumab Equalizes Short Term Outcomes in High Risk PRA Patients: Long Term Outcomes Suffer

Introduction: Alemtuzumab, a monoclonal antibody used in approximately 13% of kidney transplants, allows for early glucocorticoid withdrawal. High risk patients, defined by a presence of elevated Panel Reactive Antibody (PRA), are at greater risk for rejection, poorer graft outcomes, and have been shown to benefit from induction with alemtuzumab. T... Read More»

Naji M, Stanton AD, Ekwenna O, Mitro G, Rees M and Jorge Ortiz

Research Article: J Clin Exp Transplant 2017

DOI: 10.4172/2475-7640.1000117

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics